GlassScriptPhysician profile
Michael A Salvato
NPI 1952413445
$2,051.86
in general payments reported to CMS, 2019-2025
27 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $274 · 2021: $392 · 2022: $286 · 2023: $397 · 2024: $278 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $363.32 | 2019-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $212.36 | 2020-2024 | Nucala, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $176.99 | 2019-2024 | |
| Abbvie INC. | $159.64 | 2019-2024 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $130.04 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.51 | 2019-2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $86.30 | 2022-2023 | Hetlioz |
| Merck Sharp & Dohme LLC | $77.97 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Exact Sciences Corporation | $72.09 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $69.69 | 2023-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $62.05 | 2020-2021 | |
| Lilly USA, LLC | $59.80 | 2019-2021 | |
| Amgen INC. | $58.33 | 2019-2020 | |
| Allergan, INC. | $56.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.38 | 2020-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $46.86 | 2024 | Korlym |
| Novo Nordisk INC | $40.10 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $37.23 | 2019 | |
| Sanofi Pasteur INC. | $35.81 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $30.55 | 2021 | |
| Indivior INC. | $30.18 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $22.58 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.48 | 2021 | |
| Medtronic, INC. | $16.23 | 2024 | Intellis Adaptivestim |
| Paratek Pharmaceuticals, INC. | $15.36 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.23 | 2022 | |
| Medtronic Minimed, INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Salvato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.